Efficacy and Adverse Side Effects of Two Forms of Iron in Pregnancy
Condition(s) studied
Investigational drug(s) / intervention(s)
Ferrous fumarate: Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
Ferrous bisglycinate: Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
Study summary
This two-arm, double-blind randomized clinical trial will recruit 172 generally healthy, low-risk pregnant individuals aged 19-42 years living in Vancouver, Canada. Participants will be randomized to receive one of two forms of iron (ferrous fumarate or ferrous bisglycinate) in addition to a prenatal multivitamin (without iron) daily during their pregnancy until delivery, with optional continuation until \~4 weeks postpartum for breastmilk sample collection. Blood samples will be taken at baseline (13-25 weeks gestation) and follow-up (35-37 weeks gestation) to assess how different forms of iron impact body iron stores. Stool samples will be obtained within 1 week of both baseline and follow-up visits to assess changes in gut microbiome composition. This research will inform more specific guidelines for optimal iron supplementation practices for the prevention and treatment of iron deficiency for both mother and baby.
Eligibility
Primary outcome measure(s)
- Maternal ferritin concentration — Blood sample collected at baseline (13-25 weeks gestation) and at follow-up (35-37 weeks gestation)
µg/L; reflects body iron stores
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| BC Women's Hospital | Vancouver | British Columbia | Recruiting |
| University of British Columbia, Food, Nutrition and Health Building | Vancouver | British Columbia | Recruiting |
More University of British Columbia trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06014983 on ClinicalTrials.gov ↗ ← All trials in Canada